Evidence exists in other cancers demonstrating EGFR activity is needed for full activation of MEK and ERK downstream of mutant KRAS and this may be the first example of that in NSCLC (43), reinforcing a need to target BACE1 in this setting. The gene discussed is MAP2K7; the disease is cancer.